According to filings with the U.S. Securities and Exchange Commission, BlueWind Medical has raised $47,800,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About BlueWind Medical
BlueWind Medical is a medical technology company focused on transforming the treatment of urge urinary incontinence (UUI) through innovative, minimally invasive neuromodulation therapy. The companys primary product, Revi, is a miniature, implantable tibial neuromodulation device placed near the ankle that sends signals up the leg to the brain to help calm and control bladder symptoms without the use of drugs. Revi is designed as a long-term, outpatient, local-anesthesia procedure and offers a drug free alternative for people experiencing the gotta go feeling associated with UUI. Clinical study results highlighted on the site report that nearly 8 out of 10 participants experienced a substantial reduction in leaks after three years of using Revi, and the therapy achieved 95% patient satisfaction among those completing the study, underscoring its effectiveness and patient acceptance. Through Revi, BlueWind Medical positions itself as a provider of a transformative, patient-centric solution that aims to significantly improve quality of life for individuals living with urge urinary incontinence.

To learn more, visit https://bluewindmedical.com/
Linkedin: https://www.linkedin.com/company/bluewind-medical/

Contact:
Kerry Nelson, Chief Executive Officer
https://www.linkedin.com/in/kerry-nelson-129118a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.